Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Dec;60(12):3821-30.
doi: 10.1002/art.24986.

Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study

Tien-I Karleen Su  1 , Dinesh Khanna, Daniel E Furst, Gabriel Danovitch, Christina Burger, Paul Maranian, Philip J Clements
Affiliations
Randomized Controlled Trial

Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study

Tien-I Karleen Su et al. Arthritis Rheum. 2009 Dec.

Abstract

Objective: To assess the safety and efficacy of rapamycin in the treatment of diffuse systemic sclerosis (SSc; scleroderma).

Methods: Eighteen patients with diffuse SSc of <or=5 years duration were randomized to receive rapamycin or methotrexate (MTX) in a single-blind, 48-week study. Abnormalities in clinical and laboratory parameters were compared between the 2 treatment groups. The potential efficacy of the study drugs was evaluated by comparing results of the baseline and 48-week assessments, including the modified Rodnan skin thickness score (MRSS) and the Health Assessment Questionnaire disability index.

Results: The baseline characteristics of the patients were similar in both groups (n=9 in each). One patient in the rapamycin group who never received the study drug was excluded from the analysis. Three patients in each group withdrew from the study; 2 of the withdrawals were treatment-related (severe hypertriglyceridemia associated with rapamycin, and pancytopenia associated with MTX), and 4 were SSc-related. Hypertriglyceridemia was the most notable side effect associated with rapamycin, but it was generally well tolerated and treatable. The incidence and severity of other adverse drug reactions were comparable between the 2 groups. Within each group, the MRSS improved significantly from baseline. In the rapamycin group, the patient's global assessment showed a significant improvement from baseline, while forced vital capacity values declined from baseline. The disease activity scores at 48 weeks and the changes in these scores from baseline were not significantly different between the 2 groups.

Conclusion: Rapamycin has a reasonable safety profile in a select group of patients with scleroderma. Larger trials are needed to assess the efficacy of rapamycin in patients with early diffuse SSc.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient withdrawals and serious adverse events (SAEs) during the 48-week study. All SAEs were determined by the independent reviewer to be related to complications of SSc, with the exception of the first SAE in the MTX group (pancytopenia) which was determined to be treatment-related.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet. 2006;367(9523):1683–91. - PubMed
    1. Denton C. Therapeutic targets in systemic sclerosis. Arthritis Res Ther. 2007;9 2:S6. - PMC - PubMed
    1. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR/EUSTAR recommendations for the treatment of systemic sclerosis (SSc) [abstract] Ann Rheum Dis. 2007;66 2:213.
    1. Henness S, Wigley F. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr Opin Rheumatol. 2007;19(6):611–618. - PubMed
    1. Van den Hoogen F, Boerbooms A, Swaak A, Rasker J, van Lier H, van de Putte L. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35(4):364–72. - PubMed

Publication types